LGVN Longeveron

Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24

Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24

MIAMI, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Green, CEO of Longeveron, will be presenting at the Q1 Virtual Investor Summit.



EventQ1 Investor Summit
DateMarch 23-25, 2021
PresentationMarch 24 @ 10:00 am ET
Location



About The Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors. 



To request complimentary investor registration: please visit our website at

About Longeveron

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at .

Contact:

Crescendo Communications, LLC

Tel: 212-671-1020

Email:

Investor Summit Contact: 

Brittney Blocker at

Wire Service Contact

InvestorWire (IW)

Los Angeles, California



212.418.1217 Office



EN
19/03/2021

Underlying

LGVNLongeveron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Longeveron

 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Announces Key Leadership Updates

Longeveron® Announces Key Leadership Updates Than Powell, Chief Business Officer and head of business development, appointed Interim CEODr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of DirectorsWa’el Hashad to step down as CEO and Board memberNational search to occur for permanent CEO MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced key leadership u...

September 3, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Inves...

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 in New York City. Details for the Company’s presentation:    Date:Monday, September 8, 2025 Time:4:00 – 4:30 p.m. ET    The webcast for this conf...

August 20, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Announces Second Quarter 2025 Financial Results and Provid...

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in late 2026, if ELPIS II results are positiveStem cell therapy pipeline expanded ...

August 13, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Longeveron Announces Closing Of Up To $17.5 Million Public Offering $5.0 million upfront with up to an additional $12.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced the closing of its previously announced public offering of 5,882,354 of the Company’s Class A c...

August 11, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron Announces Up To $17.5 Million Public Offering $5.0 million upfront with up to an additional $12.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants MIAMI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced the pricing of a public offering of 5,882,354 of the Company’s Class A common stock (or pre-funded warrant...

August 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch